ATE391508T1 - Zusammensetzungen mit amphotericin b enthaltend weniger als 4 verunreinigungen - Google Patents

Zusammensetzungen mit amphotericin b enthaltend weniger als 4 verunreinigungen

Info

Publication number: ATE391508T1
Authority: AT; Austria
Prior art keywords: amphotericin; impurities; compositions; containing less; bhp
Prior art date: 2002-10-03

Application number

AT03773112T

Other languages

English (en)

Inventor

John Cleary

Robert Kramer

Original Assignee

Univ Mississippi

Univ Mississippi Medical Ct

Chapman

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-10-03

Filing date

2003-10-03

Publication date

2008-04-15

2003-10-03 Application filed by Univ Mississippi, Univ Mississippi Medical Ct, Chapman filed Critical Univ Mississippi

2008-04-15 Application granted granted Critical

2008-04-15 Publication of ATE391508T1 publication Critical patent/ATE391508T1/de

Links

APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 title abstract 4
APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 title abstract 3
229960003942 amphotericin b Drugs 0.000 title abstract 3
239000000203 mixture Substances 0.000 title abstract 2
239000012535 impurity Substances 0.000 title 1
241000124008 Mammalia Species 0.000 abstract 2
238000000034 method Methods 0.000 abstract 2
206010067484 Adverse reaction Diseases 0.000 abstract 1
229930183010 Amphotericin Natural products 0.000 abstract 1
QGGFZZLFKABGNL-UHFFFAOYSA-N Amphotericin A Natural products OC1C(N)C(O)C(C)OC1OC1C=CC=CC=CC=CCCC=CC=CC(C)C(O)C(C)C(C)OC(=O)CC(O)CC(O)CCC(O)C(O)CC(O)CC(O)(CC(O)C2C(O)=O)OC2C1 QGGFZZLFKABGNL-UHFFFAOYSA-N 0.000 abstract 1
102000004127 Cytokines Human genes 0.000 abstract 1
108090000695 Cytokines Proteins 0.000 abstract 1
206010017533 Fungal infection Diseases 0.000 abstract 1
208000031888 Mycoses Diseases 0.000 abstract 1
230000006838 adverse reaction Effects 0.000 abstract 1
229940009444 amphotericin Drugs 0.000 abstract 1
230000003833 cell viability Effects 0.000 abstract 1
230000003247 decreasing effect Effects 0.000 abstract 1
239000003937 drug carrier Substances 0.000 abstract 1
230000001988 toxicity Effects 0.000 abstract 1
231100000419 toxicity Toxicity 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Saccharide Compounds (AREA)

AT03773112T 2002-10-03 2003-10-03 Zusammensetzungen mit amphotericin b enthaltend weniger als 4 verunreinigungen ATE391508T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US41567102P	2002-10-03	2002-10-03

Publications (1)

Publication Number	Publication Date
ATE391508T1 true ATE391508T1 (de)	2008-04-15

Family

ID=32069895

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT03773112T ATE391508T1 (de)	2002-10-03	2003-10-03	Zusammensetzungen mit amphotericin b enthaltend weniger als 4 verunreinigungen

Country Status (9)

Country	Link
US (1)	US7867981B2 (de)
EP (1)	EP1551423B1 (de)
JP (1)	JP5170940B2 (de)
AT (1)	ATE391508T1 (de)
AU (1)	AU2003279776B2 (de)
CA (1)	CA2500716A1 (de)
DE (1)	DE60320283T2 (de)
MX (1)	MXPA05003616A (de)
WO (1)	WO2004030677A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20120128728A1 (en) *	2005-12-28	2012-05-24	Novartis Pharma Ag	Compositions Comprising Amphotericin B
WO2009006311A2 (en) *	2007-06-29	2009-01-08	Wisconsin Alumni Research Foundation	Structuring effect of cholesterol in peg-phospholipid micelles, drug delivery of amphotericin b, and combination antifungals
CA2737025C (en) *	2008-09-27	2012-09-04	Jina Pharmaceuticals, Inc.	Lipid based pharmaceutical preparations for oral and topical application; their compositions, methods, and uses thereof
CA2906765A1 (en)	2013-03-15	2014-09-18	Biochemics, Inc.	Topical formulations and methods for drug delivery
DE102015102210A1 (de)	2015-02-16	2016-08-18	Heraeus Medical Gmbh	Antimykotischer polymerisierbarer Knochenzement und ein Verfahren zu seiner Herstellung
CA3063870A1 (en)	2017-05-15	2018-11-22	Biochemics, Inc.	Transdermally-delivered combination drug therapy for pain
CN114605484A (zh) *	2020-12-09	2022-06-10	上海上药新亚药业有限公司	一种获得两性霉素b新晶型的纯化方法
CN112666284A (zh) *	2020-12-11	2021-04-16	南京明捷生物医药检测有限公司	一种测定蛋白溶液中两性霉素b含量的方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CH556879A (de) *	1971-04-23	1974-12-13	Le Nii Antibiotikov	Verfahren zur gewinnung und chemischen reinigung von amphoterizin b.
US4035568A (en) *	1971-06-07	1977-07-12	Rutgers Research And Educational Foundation	Derivatives of polyene macrolide antibiotics
US4049898A (en) *	1973-03-05	1977-09-20	E. R. Squibb & Sons, Inc.	Amphotericin complexes containing oxalic acid and calcium
US3965090A (en) *	1973-03-05	1976-06-22	E. R. Squibb & Sons, Inc.	Amphotericin complexes
US4054734A (en) *	1975-03-03	1977-10-18	E. R. Squibb & Sons, Inc.	Amphotericin complexes containing citric acid and calcium
US4308375A (en) *	1980-10-06	1981-12-29	E. R. Squibb & Sons, Inc.	Method for purifying water-insoluble polyene antibiotics
US4656288A (en) *	1984-03-29	1987-04-07	Takeda Chemical Industries, Ltd.	Antibiotics, their production and use
US4663167A (en) *	1984-04-16	1987-05-05	The Board Of Regents Of The University Of Texas System	Composition and method for treatment of disseminated fungal infections in mammals
US4766046A (en) *	1985-09-27	1988-08-23	Liposome Technology, Inc.	Stabilized liposome/amphotericin composition and method
JP2705175B2 (ja) *	1987-03-05	1998-01-26	ザリポソームカンパニー，インコーポレイテッド	低毒性薬剤‐脂質系
US5616334A (en) *	1987-03-05	1997-04-01	The Liposome Company, Inc.	Low toxicity drug-lipid systems
US6406713B1 (en) *	1987-03-05	2002-06-18	The Liposome Company, Inc.	Methods of preparing low-toxicity drug-lipid complexes
US4902789A (en) *	1987-10-27	1990-02-20	E. R. Squibb & Sons, Inc.	Process and composition for the purification of amphotericin B
AU598958B2 (en) *	1987-11-12	1990-07-05	Vestar, Inc.	Improved amphotericin b liposome preparation
US5194266A (en) *	1989-08-08	1993-03-16	Liposome Technology, Inc.	Amphotericin B/cholesterol sulfate composition and method
ATE176155T1 (de) *	1990-11-16	1999-02-15	Nippon Shinyaku Co Ltd	Injizierbare amphotericin b enthaltende dispersion
US5744335A (en) *	1995-09-19	1998-04-28	Mirus Corporation	Process of transfecting a cell with a polynucleotide mixed with an amphipathic compound and a DNA-binding protein
US6211140B1 (en) *	1999-07-26	2001-04-03	The Procter & Gamble Company	Cationic charge boosting systems
WO2004105697A2 (en) *	2003-05-22	2004-12-09	Molecular Transfer, Inc.	Novel lipids for transfection of nucleic acids

2003
- 2003-10-03 CA CA002500716A patent/CA2500716A1/en not_active Abandoned
- 2003-10-03 WO PCT/US2003/031390 patent/WO2004030677A1/en not_active Ceased
- 2003-10-03 EP EP03773112A patent/EP1551423B1/de not_active Expired - Lifetime
- 2003-10-03 DE DE60320283T patent/DE60320283T2/de not_active Expired - Lifetime
- 2003-10-03 MX MXPA05003616A patent/MXPA05003616A/es active IP Right Grant
- 2003-10-03 JP JP2004541663A patent/JP5170940B2/ja not_active Expired - Fee Related
- 2003-10-03 AT AT03773112T patent/ATE391508T1/de not_active IP Right Cessation
- 2003-10-03 AU AU2003279776A patent/AU2003279776B2/en not_active Ceased
- 2003-10-03 US US10/529,622 patent/US7867981B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
DE60320283T2 (de)	2009-08-27
EP1551423B1 (de)	2008-04-09
US20060105968A1 (en)	2006-05-18
EP1551423A1 (de)	2005-07-13
AU2003279776B2 (en)	2009-09-24
US7867981B2 (en)	2011-01-11
JP5170940B2 (ja)	2013-03-27
CA2500716A1 (en)	2004-04-15
WO2004030677A1 (en)	2004-04-15
MXPA05003616A (es)	2006-01-24
AU2003279776A1 (en)	2004-04-23
JP2006504716A (ja)	2006-02-09
DE60320283D1 (de)	2008-05-21

Similar Documents

Publication	Publication Date	Title
ES2733238T1 (es)	2019-11-28	Tratamiento de linfoma no Hodkings de grados intermedio y alto con anticuerpo anti CD20
GEP20074144B (en)	2007-07-10	Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
DK0683669T3 (da)	2003-01-06	Fremgangsmåder og præparater af en polymer (poloxamer) til cellereparation
NZ524767A (en)	2004-12-24	Composition for the transdermal delivery of fentanyl
DE602004016516D1 (de)	2008-10-23	Pyrimidin-2,4-dion-derivate als gonadotropin freisetzende hormon-rezeptor-antagonisten
AR090143A2 (es)	2014-10-22	Composicion farmaceutica para inhibir el crecimiento de celulas anormales
AR028833A1 (es)	2003-05-28	Compuestos inhibidores de metaloproteasas, composiciones farmaceuticas, uso para la manufactura de medicamentos, metodo de tratamiento y procedimiento para su preparacion
HUT76659A (en)	1997-10-28	A method of enhancing cellular production molecular chaperon, hydroxylamine derivatives useful for enhancing the chaperon production and the preparation thereof
BRPI0412798A (pt)	2006-09-26	uso de uma combinação de um antagonista de fator de crescimento endotelial vascular e um agente antiproliferativo, método de inibir ou reduzir o crescimento de tumor, composição farmacêutica, uso de uma combinação de um antagonista de vegf e um agente quimioterapêutico, e, artigo de fabricação
ATE344040T1 (de)	2006-11-15	Pyrophosphate zur erhöhung der zellfunktion durch schutz von muscarinrezeptoren
MXPA02010551A (es)	2003-09-25	Formulaciones y metodos de uso de mimeticos del oxido nitrico contra fenotipos de celulas malignas.
TR200102800T2 (tr)	2002-01-21	Yeni bileşikler.
IL154925A0 (en)	2003-10-31	Modulation of il-2 and il-15-mediated t cell responses
FI934000A0 (fi)	1993-09-13	Nya estrar av bi- och tricykliska aminoalkoholer, deras framstaellning och deras anvaendning i laekemedel
PL316942A1 (en)	1997-02-17	Novel pharmaceutic compositions based on taxoides
DE602004020638D1 (de)	2009-05-28	Pyrimidin-2,4-dion-derivate als gonadotropin freisetzende hormon-rezeptor-antagonisten
ATE391508T1 (de)	2008-04-15	Zusammensetzungen mit amphotericin b enthaltend weniger als 4 verunreinigungen
ES2051650A1 (es)	1994-06-16	Procedimiento para preparar un limpiador de oxigeno activo.
TR200401436T4 (tr)	2004-07-21	Monotiyogliserol, L-sistem veya tiyoglikolik asitle birlikte pemetrexed içeren farmasötik bileşim
IL155788A (en)	2013-09-30	A highly purified ifn – β active and mannitol-containing preparation, a method to make an improved stability of ifn – β active, and a method to enhance the stability of ifn – β in biologically active formulation.
ATE273704T1 (de)	2004-09-15	Ophthalmische histamin-enthaltende zusammensetzungen und deren verwendung
PT1165065E (pt)	2003-08-29	Comprimidos para degluticao com elevada concentracao de n-acetilcisteina
AU1123001A (en)	2001-05-08	Compositions and methods for preventing and treating transplant rejection
DE69619259D1 (de)	2002-03-21	Amidin- und isothioharnstoffderivate als inhibitoren der stickstoffoxid-synthase
IT1258790B (it)	1996-02-29	Alchil derivati del trazodone

Legal Events

Date	Code	Title	Description
2008-10-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties